Literature DB >> 8131816

Liposomal amphotericin-B (AmBisome) for treatment of cutaneous widespread candidosis in an infant with methylmalonic acidaemia.

S Stöckler1, H Lackner, G Ginter, W Schwinger, B Plecko, W Müller.   

Abstract

In a 10-week-old infant with vitamin B12-unresponsive methylmalonic acidaemia, cutaneous candidosis (Candida albicans) progressed rapidly despite topical antifungal treatment. After 1 week of intravenous therapy with liposomal amphotericin-B (AmBisome) the dermatitis disappeared completely and blood cultures were sterile. No side-effects were observed. This is one of the first experiences in the treatment of infants with this new antifungal agent.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8131816     DOI： 10.1007/bf01957220

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


  7 in total

1.  Liposomal amphotericin-B (AmBisome) for treatment of disseminated fungal infections in two infants of very low birth weight.

Authors:  H Lackner; W Schwinger; C Urban; W Müller; E Ritschel; F Reiterer; M Kuttnig-Haim; B Urlesberger; C Hauer
Journal:  Pediatrics       Date:  1992-06       Impact factor: 7.124

2.  Cutaneous manifestations of methylmalonic acidemia.

Authors:  R J Koopman; R Happle
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

3.  Dietary management of inborn errors of amino acid metabolism with protein-modified diets.

Authors:  E Thomas
Journal:  J Child Neurol       Date:  1992-04       Impact factor: 1.987

4.  Inhibition of bone marrow stem cell growth in vitro by methylmalonic acid: a mechanism for pancytopenia in a patient with methylmalonic acidemia.

Authors:  S Inoue; I Krieger; A Sarnaik; Y Ravindranath; M Fracassa; M J Ottenbreit
Journal:  Pediatr Res       Date:  1981-02       Impact factor: 3.756

5.  Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study.

Authors:  G Lopez-Berestein; V Fainstein; R Hopfer; K Mehta; M P Sullivan; M Keating; M G Rosenblum; R Mehta; M Luna; E M Hersh
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

6.  Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial.

Authors:  F Meunier; H G Prentice; O Ringdén
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

7.  Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates.

Authors:  J E Baley; C Meyers; R M Kliegman; M R Jacobs; J L Blumer
Journal:  J Pediatr       Date:  1990-05       Impact factor: 4.406
  7 in total
  1 in total

1.  Bacterial toxin-triggered drug release from gold nanoparticle-stabilized liposomes for the treatment of bacterial infection.

Authors:  Dissaya Pornpattananangkul; Li Zhang; Sage Olson; Santosh Aryal; Marygorret Obonyo; Kenneth Vecchio; Chun-Ming Huang; Liangfang Zhang
Journal:  J Am Chem Soc       Date:  2011-02-23       Impact factor: 15.419
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.